Delivery Order SPE2DB22D2007-SPE2DB26FH6JE
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $7,718.44 to AmerisourceBergen Drug Corp on August 26, 2025, for the supply of Atovaquone-Proguanil 250-100mg in quantities of 100 tablets. This competitively awarded, firm fixed-price contract is classified as a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion global pharmaceutical support vehicle running through December 2026. The work will be...
- The Defense Logistics Agency awarded a delivery order valued at $22,857.87 to AmerisourceBergen Drug Corp for the supply of Atovaquone-Proguanil 250-100mg tablets (100 count). This competitive, non-set-aside contract utilizes firm fixed pricing and carries an ultimate completion date of July 21, 2025. AmerisourceBergen, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform this delivery order from its corporate office location. The medication is an...
- The Defense Logistics Agency awarded a delivery order valued at $1,343.16 to AmerisourceBergen Drug Corp on April 23, 2025, for the supply of Atovaquone-Proguanil 250-100mg in quantities of 100 tablets. The contract, which is firm fixed price with an ultimate completion date of April 24, 2025, carries no set-aside designation and was competitively awarded. Performance will occur at the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $1,343.16 on September 9, 2025, for Atovaquone-Proguanil 250-100 (100 tablets), with a completion date of September 10, 2025. This is a firm fixed-price delivery order under a non-set-aside competitive procurement. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical supply needs. The order...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 2, 2025, for the supply of Atovaquone-Proguanil 250-100mg tablets (100-count units) valued at $2,350.53 under a firm fixed price contract. This antimalarial pharmaceutical product is being delivered to support military healthcare requirements, with the place of performance located in Conshohocken, Pennsylvania. The award represents a non-competitive delivery order issued under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $1,586.54 to AmerisourceBergen Drug Corp for the supply of Atovaquone-Proguanil 250-100 tablets in a quantity of 100 units. This is a firm fixed price, competitively awarded delivery order with an ultimate completion date of September 11, 2025, and represents a non-set-aside procurement. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. The product being...
- The Defense Logistics Agency awarded a delivery order valued at $9,466.11 to AmerisourceBergen Drug Corp for Atovaquone-Proguanil 250-100mg tablets (100 count) with a firm fixed price structure. This delivery order was competitively awarded with no set-aside designation and is scheduled for completion by September 8, 2025. The product will be performed and delivered from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This award represents a child contract under...
- The Defense Logistics Agency awarded a $20,147.40 delivery order to AmerisourceBergen Drug Corp on September 17, 2025, for the supply of Atovaquone-Proguanil 250-100mg in quantities of 100 tablets. The contract utilizes firm fixed price pricing with no set-aside designation, indicating competitive award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor that serves as a critical vendor for federal medical procurement, particularly...
- The Defense Logistics Agency awarded a delivery order valued at $1,119.30 to AmerisourceBergen Drug Corp for Atovaquone-Proguanil 250-100mg tablets (100-count units) on September 3, 2025, with an ultimate completion date of September 4, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The antimalarial pharmaceutical is being procured through the...
- The Defense Logistics Agency awarded a $14,922.01 delivery order to AmerisourceBergen Drug Corp for Atovaquone-Proguanil 250-100 (100 tablets) on September 12, 2025, with a completion date of September 15, 2025. This is a firm fixed price order with no set-aside designation, competitively awarded under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical. The product will be delivered to AmerisourceBergen's corporate office in Conshohocken, Pennsylvania....
- SPE2DB22D2007Indefinite Delivery Contract
- SPE2DB22D2007-SPE2DB26FH6JEDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $6,844.74 to AmerisourceBergen Drug Corp for Atovaquone-Proguanil 250-100 tablets (100 count) on October 16, 2025, with an ultimate completion date of October 17, 2025. This firm fixed-price delivery order was competitively awarded without set-aside designation to the pharmaceutical distributor's Corporate Office location in Conshohocken, Pennsylvania. The award represents a small-value transaction under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99 billion comprehensive global pharmaceutical support vehicle running through December 2026. AmerisourceBergen Drug Corp serves as a critical pharmaceutical vendor for federal military and veteran healthcare systems, supplying brand-name and generic medications, vaccines, medical devices, and specialized healthcare commodities across multiple therapeutic domains. This delivery order for Atovaquone-Proguanil—a combination antimalarial medication used for malaria prophylaxis and treatment in military personnel—exemplifies the company's role in supporting Defense Health Agency and related federal healthcare operations. The competitively awarded contract demonstrates AmerisourceBergen's continued capability to meet federal procurement requirements through the DLA's strategic pharmaceutical prime vendor contracting approach.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $6.8k | 10/16/25 |